

## Supporting Information

### **A Conjugate of Enkephalin and Temporin Peptides as a Novel Therapeutic Agent for Sepsis**

Golda A.<sup>a</sup>, Kosikowska P.<sup>b</sup>, Babyak O.<sup>a</sup>, Lech M.<sup>a,c</sup>, Wysocka M.<sup>b</sup>, Lesner A.<sup>b</sup>, Potempa J.<sup>a,d</sup>, Koziel J.<sup>a\*</sup>

<sup>a</sup>Department of Microbiology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, 30-387 Krakow, Poland;


<sup>b</sup>Faculty of Chemistry, University of Gdansk, 80-309 Gdansk, Poland;

<sup>c</sup>Department of Nephrology, Medizinische Klinik und Poliklinik IV, Klinikum der Ludwig-Maximilians-Universität München, 80366 Munich, Germany;


<sup>d</sup>Center of Oral Health and Systemic Disease, University of Louisville School of Dentistry, University of Louisville, 40202 Louisville, KY, USA;

#### **Table of contents:**

<b>Supplemental Figure 1</b>	<b>S2</b>
<b>Supplemental Figure 2</b>	<b>S2</b>



**Supplemental Figure 1.** Ability of the investigated peptides to suppress inflammatory responses by hMDMs. hMDMs were stimulated with 10 ng/ml LPS, 10 µg/ml LTA or 2 µg/ml PGN in the presence or absence of 10 µg/ml peptide. The level of **(A)** TNF-α and **(B)** IL-10 in the culture supernatants was measured in an ELISA 20 h post-stimulation. For PGN a representative result from three independent experiments using hMDMs derived from different donors is shown. Mean ± SD.  $n = 3$ . \*\*\*\* $P < 0.0001$  (TNF), \* $P < 0.035$  (IL-10); one-way ANOVA.



**Supplemental Figure 2.** Cytotoxicity test. Murine RAW 264.7 cells **(A)** and human MDMs **(B)** were stimulated with 10 ng/ml LPS in the presence of peptide at the indicated concentrations (2.5–50 µg/ml). Cells were incubated for 24 h and subjected to an MTT test. The dashed line indicates the value for untreated cells. Mean ± SEM.  $n = 3$ . # $P < 0.0001$ , \* $P < 0.01$ ; two-way ANOVA. SCR, scramble peptide.